TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2107780
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (anticoagulants, oral vasodilators, and diuretics)
Study: 2107780
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous prostacyclin (epoprostenol) for up to 18 months
Study: 28189429
Drug: Current regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current regular aspirin (>3 tablets/week)
Study: 28189429
Drug: Past regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past regular aspirin
Study: 28189429
Drug: Current postdiagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current postdiagnostic aspirin
Study: 25431855
Drug: Digital media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital media application on mobile phones showing inhalation therapy steps
Study: 23545102
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy plus 10 sessions of parasacral transcutaneous electrical neural stimulation (20 minutes, 10 Hz, 700 μs pulse, intensity based on sensitivity threshold, 3 times weekly for 10 sessions)
Study: 23545102
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (control group)
Study: 21419290
Drug: Buccal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal plus palatal infiltration (1.8 mL buccal + 0.5 mL palatal of 2% lidocaine with 1:100,000 epinephrine)
Study: 21419290
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 9121505
Drug: Cyclosporine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (5 mg/kg/day) for 7 months
Study: 3128054
Drug: Intravenous indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous indomethacin infusion (75 mg/10 h)
Study: 31821065
Drug: BEP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEP treatment (bleomycin‐etoposide‐cisplatin; n = 1,819)
Study: 28520618
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus modified directly administered antiretroviral therapy (intervention)
Study: 28520618
Drug: Atazanavir hair
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir hair concentration <2.35 ng/mg
Study: 28520618
Drug: Atazanavir hair
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir hair concentration >2.35 ng/mg
Study: 25600198
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections with no antibiotic use
Study: 25600198
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections with preinjection antibiotics only
Study: 25600198
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections with postinjection antibiotics only
Study: 25600198
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections with preinjection and postinjection antibiotics
Study: 19764942
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with a 5-grass pollen mixture, ultra-rush titration with doses of 30, 90, 150, and 300 IR every 20 min at the start of the pollen seasons, followed by 300 IR daily until the end of the pollen seasons.
Study: 12174058
Drug: Topical arnica
Normalized name: ARNICA
DrugBank: Arnica montana flower (DB14343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical arnica gel (applied twice a day for 2 weeks prior to laser treatment)
Study: 12174058
Drug: Topical arnica
Normalized name: ARNICA
DrugBank: Arnica montana flower (DB14343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical arnica gel (applied twice a day for 2 weeks after laser treatment)
Study: 12174058
Drug: Vehicle (applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (applied twice a day for 2 weeks prior to laser treatment)
Study: 12174058
Drug: Vehicle (applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (applied twice a day for 2 weeks after laser treatment)
Study: 7658007
Drug: CVC bandage
Normalized name: New-Skin Liquid Bandage
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVC bandage changed twice a week (TAW)
Study: 141326
Drug: Oral estramustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estramustine phosphate
Study: 30543311
Drug: Single mass
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single mass drug administration of azithromycin
Study: 9690973
Drug: Sertindole (12-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (12-24 mg/day)
Study: 12464464
Drug: Risperidone (4-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4-10 mg/day)
Study: 8986513
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 16 weeks
Study: 8986513
Drug: Self-treatment manual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment manual followed by up to 8 weeks of CBT (sequential group)
Study: 8375517
Drug: Vaginal ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ultrasound and blood samples for hormone parameters between 20 and 30 days after conception
Study: 3739879
Drug: Propranolol, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 80 mg orally
Study: 3739879
Drug: Diltiazem, 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 90 mg orally
Study: 3739879
Drug: Nifedipine, 20
Normalized name: Nifedipine, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 20 mg orally
Study: 30028245
Drug: Soy milk
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy milk (240 ml daily)
Study: 30846916
Drug: Scapulothoracic mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scapulothoracic mobilization + Physical Therapy
Study: 20617290
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of ascorbic acid and 400 IU of alpha-tocopherol (Tx1)
Study: 20617290
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of ascorbic acid and 400 IU of alpha-tocopherol (Tx2)
Study: 18595465
Drug: Synbiotics (Normoflorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (Normoflorin B and Normoflorin L)
Study: 11386492
Drug: Nefazodone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (400 mg/day)
Study: 3058014
Drug: Verapamil administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil administered three times daily (t.i.d.)
Study: 3058014
Drug: Verapamil administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil administered twice daily (b.i.d.)
Study: 28050917
Drug: Caffeine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4 mg.kg‐1, capsule)
Study: 18283068
Drug: Cyst(e)ine intake
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyst(e)ine intake <18 mg/kg per day
Study: 17082779
Drug: Standard remission-induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard remission-induction therapy (idarubicin plus cytarabine)
Study: 9181158
Drug: Intravenous phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phentolamine (0.5 mg/kg over 30 min)
Study: 8344801
Drug: Myopia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myopia treatment
Study: 2870010
Drug: Terbutaline (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.25 mg injected subcutaneously)
Study: 2870010
Drug: Metaproterenol (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (inhaled via metered dose inhaler)
Study: 21084039
Drug: Subcutaneous ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous ustekinumab
Study: 10489821
Drug: Repeated episodes
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated episodes of fever and antibiotic treatment in early life
Study: 10489821
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of fever episodes and antibiotic courses in asthmatic children
Study: 1881997
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg carbamazepine
Study: 6693665
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bitolterol and theophylline
Study: 20232036
Drug: GRV =
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GRV = 500 ml
Study: 20232036
Drug: GRV =
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GRV = 200 ml
Study: 16969601
Drug: Prepped CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepped CT colonography with low fiber diet, tagging, and magnesium citrate cleansing preparation
Study: 15026800
Drug: Oral capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine (1250 mg m(‐2) twice daily, days 1‐14 every 21 days; n=603)
Study: 15026800
Drug: Intravenous 5-fluorouracil/leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5-fluorouracil/leucovorin (5‐FU/LV; Mayo Clinic regimen; n=604)
Study: 15026800
Drug: Intravenous 5-fluorouracil/leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5-fluorouracil/leucovorin (5‐FU/LV)
Study: 25495503
Drug: Basic advice
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic advice regarding compliance with therapy and weight loss
Study: 16842456
Drug: NSAID prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID prescription with diagnostic codes for UGIE and endoscopic procedural codes
Study: 16842456
Drug: Algorithm validation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm validation in patients with overlapping NSAID prescription
Study: 12957759
Drug: Crystalloid cardioplegic
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid cardioplegic solution (Group A, n=9)
Study: 12957759
Drug: Warm blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm blood cardioplegic solution (Group B, n=8)
Study: 8258611
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg, administered four times at 4-hour intervals)
Study: 3929584
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg once daily) plus labetalol placebo
Study: 3929584
Drug: Labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200 mg twice daily) plus atenolol placebo
Study: 29210513
Drug: CD gel
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD gel with 1 mg/2 mL budesonide
Study: 29210513
Drug: CD gel
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CD gel (without budesonide)
Study: 29210513
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid cream
Study: 20185012
Drug: Ezetimibe added
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe added to atorvastatin 10 mg for 12 weeks
Study: 20185012
Drug: Ezetimibe added
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe added to atorvastatin 10 mg
Study: 20185012
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg or atorvastatin 40 mg
Study: 17319927
Drug: Omeprazole at
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole at half the starting dose, once daily before breakfast
Study: 17319927
Drug: Ranitidine 10
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 10 mg/kg/day, divided in two doses
Study: 15151791
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (IG) received a telephone call at 2 weeks, 2 months and 4 months in addition to normal treatment
Study: 15151791
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) received normal treatment
Study: 9752991
Drug: High WBF
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High WBF (13.5 g/day)
Study: 9752991
Drug: Low WBF
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low WBF (2 g/day)
Study: 3589921
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 milligrams every six hours) and Gentamicin (loading dose of 2.0 milligrams per kilogram, then 1.5 milligrams per kilogram every eight hours)
Study: 30704890
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B complex (B1, B6, and B12) once daily for 12 weeks
Study: 29786677
Drug: Combined rehabilitative
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined rehabilitative physiotherapeutic treatment including modulated sinusoidal currents, total wrapping with Rapan saline solution, and sedative inhalations of peony root extract.
Study: 29786677
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment (control group).
Study: 18673434
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg twice daily for 4 weeks
Study: 17852859
Drug: BIO-THREE (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIO-THREE (9 tablets per day for 4 weeks)
Study: 10386279
Drug: Isoflurane anesthesia
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane anesthesia (1.2% to 2.0% in 50% oxygen) with intravenous thiopental sodium (3 to 5 mg/kg) and succinylcholine (0.5 to 1.0 mg/kg) for tracheal intubation.
Study: 6863643
Drug: Suberythemogenic UVB
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suberythemogenic UVB with adjunctive coal tar
Study: 31077576
Drug: Novel phosphodiesterase-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel phosphodiesterase-4 inhibitor (CHF6001)
Study: 28296732
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg oxycodone
Study: 28296732
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg oxycodone
Study: 28296732
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg oxycodone
Study: 28296732
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg oxycodone
Study: 28296732
Drug: 0.159 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.159 mg/kg oxycodone (ED95)
Study: 28296732
Drug: 0.020 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.020 mg/kg oxycodone (ED50)
Study: 28296732
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 mg/kg oxycodone)
Study: 26567274
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Bupropion Sustained Release
Study: 26567274
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Bupropion Sustained Release
Study: 23103313
Drug: Seizure free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seizure free status, one or no antiepileptic drug (AED), EEG without epileptiform abnormalities
Study: 23103313
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of enzyme‐inducing AEDs
Study: 17878762
Drug: High-dose hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hydrocortisone
Study: 17878762
Drug: Bradykinin, acetylcholine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin, acetylcholine, sodium nitroprusside infusions
Study: 3542618
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with one or two daily doses of insulin (Group A)
Study: 3542618
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment with nine daily injections of fast‐acting insulin for ten days and for 7 days after 15 months (Group B)
Study: 3542618
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment with nine daily injections of fast‐acting insulin (Group B)
Study: 28855419
Drug: PRO40 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO40 (40 g casein)
Study: 28855419
Drug: PRO20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO20 (20 g casein)
Study: 28855419
Drug: PRO20+LEU (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO20+LEU (20 g casein plus 1.5 g leucine)
Study: 25543822
Drug: Ceramide 2-containing
Normalized name: ceramide 2
DrugBank: Ceramide NG (DB14706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramide 2-containing hydrocolloid dressings with varying amounts of tackifying agent (TA)
Study: 10669692
Drug: RCP-directed treatments
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCP-directed treatments (Firm A, n = 239)
Study: 10669692
Drug: Physician-directed treatments
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician-directed treatments (Firms B and C)
Study: 28851443
Drug: Two approaches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two approaches to speech and language therapy (SLT)
Study: 21346062
Drug: Dietary methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary methionine restriction (MR) at 2 mg methionine/kg body weight per day
Study: 21346062
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 33 mg methionine/kg body weight per day
Study: 11128915
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (with and without DFDBA)
Study: 9069293
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy (EBRT) alone (Group 1)
Study: 9069293
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of neoadjuvant combination therapy (LHRH‐agonist + Flutamide) prior to EBRT (Group 2)
Study: 9069293
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy 3 months before, during, and 6 months after EBRT (Group 3)
Study: 8450178
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose L-carnitine (6 gr per day for two weeks)
Study: 30149474
Drug: Gastric lavage
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric lavage (GL) with 10 ml/kg of normal saline
Study: 28598927
Drug: ANI-guided fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ANI-guided fentanyl administration
Study: 8777885
Drug: Cryotherapy (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy (standard therapy using cool packs)
Study: 7116616
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (aerosol and powder)
Study: 7116616
Drug: Counting of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counting of sneezes after medication
Study: 21480950
Drug: telcagepant 500
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant 500 mg
Study: 7437212
Drug: Normovolaemic haemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normovolaemic haemodilution (23 +/- 2 ml/kg of blood withdrawn, replaced by twice volume with 4% albumin and Ringer lactate solution)
Study: 30851351
Drug: Hyperbaric Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric Oxygen (HBO) administered in 30 daily dives at 100% oxygen to a pressure of 2.4 atmospheres absolute for 80 to 90 minutes.
Study: 30851351
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HBO treatment).
Study: 9234029
Drug: Women who
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who intentionally omitted or reduced insulin
Study: 3688570
Drug: IgG anti-cow's
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG anti-cow's milk antibody
Study: 3688570
Drug: Cow's milk-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk-specific IgG antibody
Study: 29172715
Drug: Telemonitoring: weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring: weekly assessment of transmitted HBP by physicians and treatment adjustment upon office visits
Study: 29172715
Drug: Telemedicine: online
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine: online communication instead of office visits to adjust medication using telemonitored HBP
Study: 22551811
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg hemagglutinin (HA) alone
Study: 22551811
Drug: 1.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 μg HA and Matrix M adjuvant (50 μg)
Study: 22551811
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg HA and Matrix M adjuvant (50 μg)
Study: 22551811
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg HA and Matrix M adjuvant (50 μg)